登录新浪财经APP 搜索【信披】查看更多考评等级 | | | 1月4日重要公告摘要 | | --- | --- | --- | | 类型 | 公司 | 主要内容 | | 今日聚焦 | 生益科技 | 签订45亿元高性能覆铜板项目投资意向协议 | | | 天龙股份 | 拟2. 32亿元收购4D毫米波雷达公司苏州豪米波54. 87%股权 | | | 铜陵有色 | 米拉多铜矿二期工程延期 预计将对公司2026年的经营业绩 产生一定影响 | | 投资签约 | 龙蟠科技 | 拟投资20亿元建设高性能锂电池正极材料项目】 拟购买高速高频载板生产商甬强科技控制权股票停牌 后者 高端产品已通过Intel、华为等认证 | | | 延江股份 | | | | 中坚科技 | 拟开展智能机器人合作开发项目 | | | 梦网科技 | 与神州六合签署6000万元无人机研发生产合作协议 | | | 鹰龙股份 | 拟合资设立算力中心液冷公司并签署投资意向协议 | | | 九鼎新材 | 拟投资2.46亿元建设大型兆瓦级风电叶片生产线项目 | | 股权变动 | *ST中装 | 实际控制人变更为龙吉生 | | | 海正药业 | 股东国贸集团拟协议转让 ...

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, indicating an "Overweight" rating, suggesting that the industry is expected to outperform the overall market [30]. Core Insights - The report highlights a 2.1% decline in the Shenwan Pharmaceutical and Biological Index, while the Shanghai Composite Index rose by 0.13% during the same period, ranking the pharmaceutical sector 28th among 31 sub-industries [3][4]. - The report emphasizes the anticipated large-scale production of brain-computer interface devices by Neuralink in 2026, predicting rapid development in the brain-computer interface sector and encouraging investment in related companies [3][13]. - Recent collaborations and advancements in drug development are noted, including a strategic partnership between Heptares Therapeutics and BlueNac to develop next-generation radionuclide drug conjugates, and the acceptance of clinical trial applications for innovative drugs by various companies [14][17]. - The report mentions significant licensing agreements, such as Zai Lab granting AbbVie exclusive rights to ZG006 outside Greater China, with potential payments reaching up to $1.235 billion [16]. - The report suggests investment opportunities in the CRO sector due to a recovering environment for innovative drugs, highlighting companies like Tigermed, Nanjing Legend, and others [3][24]. Market Performance - The pharmaceutical sector's overall valuation stands at 28.6 times earnings, ranking 10th among 31 Shenwan primary industries [7][24]. - The report details the performance of various sub-sectors within the pharmaceutical industry, with declines noted across multiple categories, including a 4.1% drop in offline pharmacies and a 2.6% drop in medical devices [4][7]. Recent Key Events - Neuralink's announcement regarding the mass production of brain-computer interface devices is expected to accelerate the development of the industry, supported by government policies aimed at fostering innovation [13]. - Heptares Therapeutics and BlueNac's collaboration aims to leverage advanced drug delivery systems to enhance treatment efficacy while minimizing damage to surrounding healthy tissues [14]. - The acceptance of clinical trial applications for innovative drugs, such as FB7013 targeting IgA nephropathy, indicates ongoing advancements in the pharmaceutical sector [17]. IPO Dynamics - New Tong Pharmaceutical's IPO application has been accepted, with a post-investment valuation of 3.81 billion yuan, focusing on significant liver disease treatments [18]. - Jingze Biopharmaceutical's IPO application has also been accepted, with a post-investment valuation of 3.18 billion yuan, specializing in reproductive and ophthalmic medications [21][22].

格隆汇1月4日丨海正药业(600267.SH)公布，持股5%以上股东浙江省国际贸易集团有限公司（简称"国贸 集团"）拟通过公开征集转让的方式协议转让其直接持有的全部公司股份72,673,907股，约占公司总股本 的6.06%，股份性质全部为无限售条件流通股。若本次公开征集转让实施完成，国贸集团将不再直接持 有公司股份。 ...

Group 1 - Zhongmin Resources has completed the construction of a 30,000-ton high-purity lithium salt project, which began trial production on January 2, 2026, with a total investment of 121 million yuan [2] - Shaoyang Hydraulic's acquisition of 100% of Chongqing Xincheng Hangrui Technology has been accepted by the Shenzhen Stock Exchange [3] - Xingqi Eye Medicine received approval for the supplementary application of atropine sulfate eye drops, aimed at delaying myopia progression in children aged 6 to 12 [4] Group 2 - Bailong Oriental expects a net profit of 600 million to 700 million yuan for 2025, representing a year-on-year increase of 46.34% to 70.73% [5] - Magmite's application for a private placement has been approved by the China Securities Regulatory Commission [6] - *ST Aowei's stock may face delisting risk due to a market capitalization below 500 million yuan [7] Group 3 - Changyuan Power plans to invest 572 million yuan in a wind power project in Hubei Province, with a planned capacity of 100 MW [8] - Haizheng Pharmaceutical's shareholder intends to transfer 6.06% of the company's shares [9] - Fusheng Technology has received approval for a share issuance to acquire assets and raise matching funds [10] Group 4 - Tenglong Co. plans to establish a joint venture for a liquid cooling company with an investment of 30 million yuan [11] - *ST Tianshan reported sales of live livestock amounting to 24.6 million yuan in December 2025, with significant year-on-year growth [12] - Hengxin Oriental's controlling shareholder has released a pledge of 0.91% of shares [13] Group 5 - Peking University Pharmaceutical plans to distribute a cash dividend of 1.68 yuan per 10 shares, totaling 100 million yuan [14] - Tianlong Co. intends to acquire a 54.87% stake in Suzhou Haomi Bo for 232 million yuan [15] - Jinggong Technology's first carbon fiber production line has successfully commenced trial production [16] Group 6 - Shanfeng Cement has terminated its investment and asset acquisition plans due to disagreements on asset valuation [17] - Shengyang Co. plans to acquire 51% of Shenzhen Daren High-tech for approximately 74.47 million yuan [18] - Xinxiang Chemical has resumed production of biomass cellulose filament after equipment upgrades [19] Group 7 - Jiuding New Materials plans to invest 246 million yuan in a wind turbine blade production line project [20] - Hunan Baiyin's shareholder has reduced its stake to below 5% [21] - Century Huatong intends to repurchase shares worth 300 million to 600 million yuan [22] Group 8 - Jincai Hulin plans to acquire 51% of Wuxi Sanli for 63.43 million yuan [23] - Jiamei Packaging's stock has experienced abnormal trading fluctuations, but no significant undisclosed information has been found [25] - Guoguang Electric's general manager has resumed duties after the lifting of restrictions [26] Group 9 - Shengxing Co. is planning a private placement for 2025, with no significant changes in its operational situation [27] - *ST Meigu has applied to lift the delisting risk warning after completing its restructuring plan [28] - CATL has repurchased 15.99 million A-shares for a total of 4.386 billion yuan [29] Group 10 - Phoenix Shipping's actual controller has been released from mandatory measures [30] - Guoxin Technology's new neural network processor has successfully passed internal testing [31] - Yanjing Co. plans to acquire control of Ningbo Yongqiang Technology, leading to a stock suspension [32]

北京商报讯（记者 丁宁）1月4日晚间，海正药业（600267）发布公告称，公司持股5%以上股东浙江省 国际贸易集团有限公司（以下简称"国贸集团"）拟通过公开征集转让的方式协议转让其直接持有的全部 公司股份7267.39万股，约占公司总股本的6.06%，股份性质全部为无限售条件流通股。若本次公开征集 转让实施完成，国贸集团将不再直接持有公司股份。 ...

格隆汇1月4日丨海正药业(600267.SH)公布，截至2025年12月月底，公司已累计回购股份721.61万股，占 公司总股本的比例为0.60%，购买的最高价为10.55元/股、最低价为8.92元/股，已支付的总金额为 67,992,848.98元(不含交易费用)。 ...

关于持股 5%以上股东拟通过公开征集转让方式协议 转让公司股份的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600267 证券简称：海正药业 公告编号：临 2026-02 号 浙江海正药业股份有限公司 重要内容提示： 根据《上市公司国有股权监督管理办法》等相关规定，本次公开征集转让的 价格将不低于本次公开征集转让提示性公告日（2026年1月5日）前30个交易日的 浙江海正药业股份有限公司董事会 二○二六年一月五日 每日加权平均价格的算术平均值及最近一个会计年度公司经审计的每股净资产 值两者之中的较高者。最终转让价格将依据相关法律法规，以公开征集并经国有 资产监督管理部门等有权机构批复的结果确定。在本次公开征集转让完成前，如 果公司发生派息、送股、转增股本、配股等除权、除息事项，则转让股份的价格 和数量相应调整。 本次公开征集转让尚需取得国有资产监督管理部门等有权机构的批准，由国 有资产监督管理部门审批后方可进入公开征集转让程序。因此，本次公开征集转 让的实施能否取得国有资产管理部门等有权机构的批准及批 ...

证券代码：600267 证券简称：海正药业 公告编号：临 2026-01 号 浙江海正药业股份有限公司 重要内容提示： | 回购方案首次披露日 | 2025/5/13 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2025 5 5 | 12 | 日~2026 | 年 | 月 | 日 11 | | 预计回购金额 | 5,000万元~10,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 7,216,100股 | | | | | | | 累计已回购股数占总股本比例 | 0.60% | | | | | | | 累计已回购金额 | 67,992,848.98元 | | | | | | | 实际回购价格区间 | 8.92元/股~10.55元/股 | | | | | | 一、 回购股份的基本情况 关于第四次以集中竞价交易方式回购公司股份的进展 公 ...

Core Insights - The collaboration between Insilico Medicine and Haizheng Pharmaceutical has achieved a significant milestone by nominating a preclinical candidate compound (PCC) within approximately 8 months of their strategic partnership [1][2][3] Group 1: Collaboration Details - The partnership began in April 2025, focusing on innovative drug development through the integration of AI technology and traditional drug discovery methods [1] - Insilico Medicine is responsible for early-stage research, including target identification, lead compound discovery, and preclinical studies, while Haizheng Pharmaceutical will handle the clinical trial application and subsequent clinical trial processes [1][2] Group 2: Project Progress and Impact - Within the 8-month collaboration, Insilico Medicine efficiently advanced the early research and completed the necessary preclinical studies, meeting the PCC nomination standards set by both companies [2] - The project highlights the potential of AI-driven innovation in drug development, particularly in addressing unmet clinical needs in novel target areas [2][3] Group 3: Strategic Implications - The successful nomination of the PCC within a short timeframe validates the delivery capabilities of Insilico Medicine and the collaborative efficiency of both companies [3] - This collaboration serves as a representative case for local enterprises exploring new pathways in drug development through the synergy of AI platforms and pharmaceutical industrialization capabilities [3]

Group 1 - The collaboration between Insilico Medicine and Haizheng Pharmaceutical has achieved a milestone by nominating a preclinical candidate compound (PCC) within approximately 8 months of their strategic partnership [1][2] - The partnership began in April 2025, focusing on deep collaboration in drug discovery and development by integrating AI technology with traditional drug development advantages [1] - Insilico Medicine is responsible for early-stage research, including target identification, lead compound discovery, and preclinical studies, while Haizheng Pharmaceutical will handle clinical trial application support and subsequent clinical trial implementation [1] Group 2 - Insilico Medicine's Pharma.AI platform has efficiently advanced early-stage research, producing preclinical data that meets the PCC nomination standards set by both companies [2] - The rapid achievement of the PCC nomination demonstrates the potential of AI-driven innovation in early drug development, particularly in addressing unmet clinical needs [2][3] - Haizheng Pharmaceutical expressed strong impressions regarding the efficiency and quality of the project, highlighting the integration of traditional pharmaceutical experience with cutting-edge AI technology as a key step in their digital transformation [3]